


## Supplemental material

**Table S1.** Patient characteristics.

Pat, patient; GVHD, graft-versus-host disease; MDS, myelodysplastic syndrome; PTLD, post-transplant lymphoproliferative disorder; CML, chronic myeloid leukemia; Bu, busulphan; CMV, cytomegalovirus; ALL, acute lymphatic leukemia; CLL, chronic lymphatic leukemia; TBI, total body irradiation; ARDS, acute respiratory distress syndrome

Pat.	Sex	Age (year)	Diagnosis	Onset GVHD grade $\geq$ II (days after HSCT)	Maximal grade of GVHD	Start posaconazole, days after HSCT	Dead (days after HSCT)	Signs of invasive fungal infection at autopsy	Cause of death
1	M	64	MDS	30	I-II	65	70	Invasive mold infection in trachea	PTLD
2	M	61	CML	14	IV	182	186	No	GVHD, CMV pneumonitis
3	M	38	ALL	24	III	35	66	No	PTLD
4	M	65	CLL	11	II	22	64	No	ARDS, relapse CLL
5	M	37	Lymphoma	21	IV	24	210	No	GVHD
6	M	40	Lymphoma	91	III-IV	92	111	No	GVHD, CMV infection
7	M	52	Lymphoma	41	III	70	92	No	Pneumonia, relapse lymphoma

**Figure S1. Intra-individual pattern of posaconazole tissue distribution.** Each dot represents one patient. Tissue concentrations are shown in relation to the liver concentration which is set to 1. The lines represent median values.



**Figure S2.** Relationship between concentrations in lung tissues and plasma.

